HALO News & Analysis

Halozyme Therapeutics Projects $1.7–$1.8 Billion Revenue Growth in 2026

Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced the appointment of David Ramsay as interim CFO on March 12, 2026. The company forecasts revenues between $1.7 billion and $1.8 billion for the year, marking a projected increase of 22% to 30%. Notably, CEO Helen Torley projected royalties from the ENHANZE drug-delivery system to reach $1.1–$1.2 billion. Halozyme also has seven ENHANZE products in development and aims for 40 drugs to be approved or in development by 2028, highlighting its growth trajectory despite the ongoing patent litigation with Merck.